BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
0.9408
+0.0207 (2.25%)
Oct 19, 2026, 11:33 AM EDT - Market open
BioCardia Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
14.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
| Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
| Dec 31, 2018 | 625.00K | 146.00K | 30.48% |
| Dec 31, 2017 | 479.00K | -97.00K | -16.84% |
| Dec 31, 2016 | 576.00K | -328.00K | -36.28% |
| Dec 31, 2015 | 904.00K | 477.00K | 111.71% |
| Dec 31, 2014 | 427.00K | 159.00K | 59.33% |
| Dec 31, 2013 | 268.00K | 206.00K | 332.26% |
| Dec 31, 2012 | 62.00K | 50.00K | 416.67% |
| Dec 31, 2011 | 12.00K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| SeaStar Medical Holding | 1.71M |
| Lipocine | 1.57M |
| Daré Bioscience | 1.37M |
| Allarity Therapeutics | 345.00K |
| Vyome Holdings | 129.73K |
BCDA News
- 1 hour ago - BioCardia announces FDA acceptance of Helix pre-submission package - TheFly
- 2 hours ago - BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter - GlobeNewsWire
- 12 days ago - BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting - GlobeNewsWire
- 18 days ago - BioCardia files revised de novo pre-submission for FDA approval of Helix - TheFly
- 18 days ago - BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter - GlobeNewsWire
- 26 days ago - BioCardia provides update on near term milestones for CardiAMP, Helix - TheFly
- 26 days ago - BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission - GlobeNewsWire
- 5 weeks ago - BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire